RELMADA THERAPEUTICS, INC. Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31)
RELMADA THERAPEUTICS, INC. (RLMD) had Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) of $975.00 thousand as of 2012-04-30, per its 8-K filed 2014-05-27.
Discontinued › Notes
us-gaap:LineOfCreditFacilityAmountOutstanding · last filed 2014-05-27
- 2012-04-30: Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) $975.00K.
| Period end | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) |
|---|---|
| 2012-04-30 | $975.00K 8-K · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |